JNJ's Rybrevant Scores FDA Approval In Lung Cancer Patients With EGFR Exon 20 Mutation

Comments
Loading...
  • The FDA has approved Janssen Pharmaceutical Companies' a unit of Johnson & Johnson JNJ Rybrevant (amivantamab-vmjw) for a subset of non-small cell lung cancer (NSCLC).
  • The approval covers adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
  • Researchers evaluated Rybrevant's efficacy in a study of 81 patients.
  • The overall response rate was 40% was reported in the treatment arm. The median duration of response was 11.1 months, with 63% of patients having a response of 6 months or more.
  • Price Action: JNJ shares are up 0.10% at $171.24 during the market session on the last check Friday.
  • Related content: Benzinga's Full FDA Calendar
JNJ Logo
JNJJohnson & Johnson
$162.59-0.25%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum56.92
Growth77.20
Quality29.73
Value20.39
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: